JW
Therapeutic Areas
Design Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DT-216 | Friedreich Ataxia (FRDA) | Phase 1 |
| GeneTAC Platform for DM1 | Myotonic Dystrophy Type 1 (DM1) | Preclinical |
Leadership Team at Design Therapeutics
JS
Joao Siffert, M.D.
President, Chief Executive Officer, and Director
PS
Pratik Shah, Ph.D.
Executive Chairperson of the Board of Directors
AA
Arthur A. Levin, Ph.D.
Chief Scientific Officer
JS
Javier San Martin, M.D.
Chief Medical Officer
KB
Kathleen B. Yates
Senior Vice President, Corporate Development and Strategy
MD
Michael D. Ehlers, M.D., Ph.D.
Board Director
CG
Carol G. Gallagher, Pharm.D.
Board Director
AB
Ajay Bansal, Ph.D.
Board Director
KS
Katherine Stueland
Board Director
MD
Michael D. Eklund, M.S., J.D.
Chief Legal Officer and Corporate Secretary